ARTL - Relief For Cancer Patients In Artelo Bioscience Pipeline

• Exciting opportunities are emerging for new therapies that target the recently identified endocannabinoid system, which governs numerous cellular processes in human body.
• To economically build portfolio value, Artelo’s business model relies on both in-licensed and internally developed compounds and contracts for clinical services.
• Patents awarded to Artelo protect two promising small molecule candidates and a cocrystal of cannabidiol.
• Human clinical trials are underway for a therapeutic candidate targeting cancer-related anorexia, a worrisome condition that has no established treatment and a market value expected to grow near 10% CAGR through 2030.
• Artelo has sufficient capital resources to reach its next value-generating milestone at the end of the Phase 1b/2a clinical trial for cancer-related anoxia therapy. Favorable clinical trial data could serve as strong valuation catalyst.

For further details see: